Evidence map›Paper›PMID 28665418›Full record

Trial reportBlood cancer journal2017

Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma.

T Dosani, F Covut, R Beck, J J Driscoll, M de Lima, E Malek

Abstract readClinical TrialLetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Monocyte or white blood cell counts and βTherapeutic advances in hematology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

T DosaniDepartment of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
F CovutDepartment of Medicine, Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
R BeckDepartment of Pathology, Clinical Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
J J DriscollDepartment of Medicine, University of Cincinnati Cancer Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
M de LimaDepartment of Medicine, Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
E MalekDepartment of Medicine, Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Funding

TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2M
NCI NIH HHS K12 CA076917
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LymphocytesMonocytesMultiple MyelomaAdultAgedAged, 80 and overBiomarkersDisease-Free SurvivalFemaleHumansLymphocyte CountMaleMiddle AgedSurvival RateBiomarkers

Identifiers

PMID28665418
PMCPMC5520407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.